A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
All content for The Life Challenges Podcast is the property of Christian Life Resources and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
From Transition to Truth: A Journey with Katie Coblentz | Part 1
The Life Challenges Podcast
41 minutes
2 months ago
From Transition to Truth: A Journey with Katie Coblentz | Part 1
Katie Coblentz shares her powerful journey through gender transition and detransition, revealing how her identity as a baptized child of God ultimately became her anchor when everything else fell apart. She describes the complex path from childhood confusion to medical transition and back, offering unique insights from someone who has lived on both sides of this profound life experience. "I'm a baptized child of God," Katie says, describing the moment of clarity that came after years of conf...
The Life Challenges Podcast
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
